UPDATE 1-Biopharmaceutical firm Parabilis Medicines files for US IPO

Adds details throughout

May 19 (Reuters) - Biopharmaceutical company Parabilis Medicines has filed for an initial public offering in the United States, according to a regulatory filing on Tuesday.

The IPO comes at a time when investor appetite for new offerings has improved following several high-profile market debuts.

Parabilis is a clinical-stage biopharmaceutical company developing Helicons, a novel class of therapies designed to target historically undruggable proteins. The company's lead drug candidate is zolucatetide.

Parabilis will list on the Nasdaq under the symbol "PBLS".

Leerink Partners, BofA Securities and Evercore ISI are among the underwriters for the offering.


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.